Ozempic Receives Positive EU Opinion for Kidney Disease Risk Reduction
Ozempic Shows Promise in slowing Kidney Disease Progression in Type 2 Diabetes Patients
New Data Could Led to expanded Use of Popular Weight-Loss Drug
(New York, NY) – A groundbreaking clinical trial has shown that Ozempic®, a popular medication for type 2 diabetes, can significantly slow the progression of chronic kidney disease (CKD) in patients. This positive news comes from Novo Nordisk, the drug’s manufacturer, following a positive opinion from the European Medicines Agency (EMA).The FLOW trial,a large-scale study,found that Ozempic® (semaglutide 1.0 mg) reduced the risk of kidney disease progression,cardiovascular and renal death by a remarkable 24% compared to a placebo.
“Around 40% of people with type 2 diabetes develop chronic kidney disease,” said Martin Holst Lange, Executive Vice President of growth at Novo Nordisk. “There is therefore a need for treatments that can help slow the progression of kidney disease.”
The trial also revealed promising secondary results.Ozempic® demonstrated an 18% reduction in the risk of major cardiovascular events and a 20% reduction in the risk of all-cause mortality.
These findings position Ozempic® as the first and only GLP-1 receptor agonist to show a reduced risk of kidney disease progression in adults with both type 2 diabetes and CKD.
Novo Nordisk has submitted a similar submission to the U.S. Food and Drug Governance (FDA) and expects a decision in the first half of 2025. If approved, this label expansion could significantly impact the treatment landscape for millions of Americans living with type 2 diabetes and CKD.
Ozempic Shows Promise in Slowing Kidney Disease Progression in Type 2 Diabetes Patients
Could New Data Led too expanded Use of Popular Weight-Loss Drug?
New York, NY - Exciting new data from a large-scale clinical trial suggests that Ozempic® (semaglutide 1.0 mg) may be a game-changer in the fight against chronic kidney disease (CKD) in individuals with type 2 diabetes. Novo Nordisk, the manufacturer of Ozempic®, announced the positive results after receiving a positive opinion from the European Medicines Agency (EMA).
The FLOW trial demonstrated that Ozempic® substantially reduced the risk of kidney disease progression, cardiovascular and renal death by 24% compared to a placebo. This groundbreaking finding could have meaningful implications for the millions of people worldwide living with both type 2 diabetes and CKD.
“Around 40% of people with type 2 diabetes develop chronic kidney disease,” said Martin Holst Lange, Executive vice President of progress at Novo Nordisk. ”There is thus a need for treatments that can definately help slow the progression of kidney disease.”
Adding to the positive results, the trial also revealed that Ozempic® demonstrated an 18% reduction in the risk of major cardiovascular events and a 20% reduction in the risk of all-cause mortality.
These findings position Ozempic® as the first and only GLP-1 receptor agonist to show a reduction in the risk of kidney disease progression in adults with both type 2 diabetes and CKD.
Novo Nordisk has submitted a similar submission to the U.S. Food and Drug Governance (FDA) and anticipates a decision in the first half of 2025. If approved, this label expansion could significantly impact treatment options for millions of Americans living with type 2 diabetes and CKD.